High resolution computerized tomography of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis patients Presented in part at the European Respiratory Society Annual Congress, Glasgow, Scotland from September 4 to 8, 2004, and at North American Cystic Fibrosis Conference, St. Louis, MO from October 14 to 18, 2004.

Abstract

To evaluate the sensitivity of high-resolution computerized tomography (HRCT) of the chest compared to spirometry measures in evaluating the effects of tobramycin solution for inhalation (TSI) in cystic fibrosis (CF) patients.Thirty-two subjects ≥6 years old with mild to moderate CF lung disease were enrolled in a randomized, double-blind, placebo-controlled pilot study. Duration was 28 days; 31 subjects completed the study.HRCT scores decreased 4.06 ± 3.20 (mean ± SD) for TSI and decreased 0.17 ± 1.78 for placebo subjects ( P = 0.13). Mean forced expiratory flow during middle half of forced vital capacity (FEF 25%–75% ) predicted increased 6.08 ± 4.86 for TSI and decreased 0.60 ± 2.34 for placebo ( P = 0.23). Percentage forced expiratory volume in 1 s (FEV 1 ) predicted increased slightly for both TSI and placebo (1.29 ± 3.33 for TSI and 1.17 ± 1.4 for placebo) ( P = 0.97). Two of eight HRCT component scores (atelectasis and inhomogeneity) were observed to be highly discordant with observed HRCT global total score and other HRCT component scores. A modified total score was calculated by dropping them from the global total score. The modified HRCT total scores decreased 6.68 ± 3.09 for TSI subjects and increased 0.02 ± 2.0 for the placebo subjects ( P = 0.07). Sample sizes were calculated to show statistical significance by differences in modified total HRCT scores, global total HRCT scores, FEF 25%–75% predicted or FEV 1 % predicted. A total of 60, 100, 200, and over 800 patients would be necessary respectively.HRCT can be a useful measure of change in CF pulmonary disease, requiring a smaller sample size than that required to show treatment effect by pulmonary function testing (PFT) alone. Pediatr Pulmonol. 2006, 41: 1129–1137. © 2006 Wiley-Liss, Inc.